-+ 0.00%
-+ 0.00%
-+ 0.00%

Replimune Group Inc. releases IGNYTE trial data on RP1 plus nivolumab in anti-PD-1-failed melanoma

Reuters·11/07/2025 22:04:42

Please log in to view news